World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
39222
World Ranking
16386
National Ranking
8244

Overview

Neil P. Shah is affiliated with the University of California, San Francisco in the United States. Their primary field of study is Medicine, with a significant focus on Hematology, Genetics, and Oncology, as well as Surgery and Rheumatology. Shah's research reflects a broad engagement with the study of blood-related diseases and cancer.

The scientist's main research topics include:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Myeloid Leukemia Research
  • HER2/EGFR in Cancer Research
  • Eosinophilic Disorders and Syndromes
  • Venous Thromboembolism Diagnosis and Management
  • Diagnosis and Treatment of Venous Diseases

Shah has contributed to multiple publications spanning several recognized medical journals. The most frequent venues for their work include:

  • Blood
  • Leukemia
  • European Journal of Medicinal Chemistry
  • Haematologica
  • Cureus

Among their recent papers are:

  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia, 2020, JAMA Oncology
  • Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia, 2022, American Journal of Hematology
  • Six-Month Outcomes of Mechanical Thrombectomy for Treating Deep Vein Thrombosis: Analysis from the 500-Patient CLOUT Registry, 2023, CardioVascular and Interventional Radiology
  • Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials, 2024, Leukemia

Shah frequently collaborates with other researchers in their field. Notable coauthors include:

  • Michael J. Mauro
  • Jorge E. Cortés
  • Michael W. Deininger
  • Javier Pinilla-Ibarz
  • Delphine Réa

Best Publications

  • Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

    Neil P. Shah;Chris Tran;Francis Y. Lee;Ping Chen

  • Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato

  • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

    Neil P. Shah;John M. Nicoll;Bhushan Nagar;Mercedes E. Gorre

  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

    Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Dynamics of chronic myeloid leukaemia.

    Franziska Michor;Timothy P. Hughes;Yoh Iwasa;Susan Branford

  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Jorge E. Cortes;Giuseppe Saglio;Hagop M. Kantarjian;Michele Baccarani

  • Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

    Todd A. Carter;Lisa M. Wodicka;Neil P. Shah;Anne Marie Velasco

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

    Catherine C. Smith;Qi Wang;Chen Shan Chin;Sara Salerno

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle

    J. B. M. Jowett;V. Planelles;B. Poon;N. P. Shah

  • Gene expression changes associated with progression and response in chronic myeloid leukemia

    Jerald P. Radich;Hongyue Dai;Mao Mao;Vivian Oehler

  • Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

    Neil P. Shah;Hagop M. Kantarjian;Dong Wook Kim;Delphine Réa

  • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

    Jorge E Cortes;Philippe Rousselot;Dong Wook Kim;Ellen Ritchie

  • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

    Hagop M Kantarjian;Ricardo Pasquini;Nelson Hamerschlak;Philippe Rousselot

  • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

    A. Hochhaus;M. Baccarani;M. Deininger;J. F. Apperley

Frequent Co-Authors

Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Michael W. Deininger
Michael W. Deininger University of Utah
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Michele Baccarani
Michele Baccarani University of Bologna
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Victor M. Rivera
Victor M. Rivera Takeda (Japan)
Charles L. Sawyers
Charles L. Sawyers Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering medicine in the USA, there are many related online degrees and career pathways worth exploring. These options can offer faster, flexible, and more affordable routes within the healthcare sector.

If you're interested in mental health, some of the shortest online pmhnp programs allow you to quickly become a Psychiatric Mental Health Nurse Practitioner, expanding your career potential. Similarly, those wanting to learn about the business side of healthcare can pursue a healthcare administration degree online, which prepares graduates for management roles.

For advanced leadership positions, explore online mha programs affordable from accredited universities that provide high-quality education at a lower cost. If your goal is becoming a clinical leader, the cheapest dnp online programs can help you achieve a Doctor of Nursing Practice degree without excessive student debt.

These online programs can provide valuable credentials for diverse healthcare careers while offering flexibility for working adults or those seeking cost-effective pathways into the industry.

Best Scientists Citing Neil P. Shah

Trending Scientists